界面新闻记者 |唐卓雅界面新闻编辑 |谢欣诺和诺德称去年年底终止研发的晚期肾病新药Ocedurenone因受到误导,要求KBP Biosciences(以下简称“KBP”)赔偿高达8.3亿美元。2月14日,据新加坡法院裁决,批准原告诺和诺德申请的针对KBP及其创始人兼执行董事长黄振华的全球资产冻结令。该冻结令是为了支持诺和诺德打算在纽约对被告提起的仲裁,要求赔偿8.3亿美元。图片来源:新加坡法院...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.